@article{Alroomi_M-2022_101201,
title = {In-hospital mortality rates in SARS-CoV-2 patients treated with enoxaparin and heparin},
author = {Alroomi, M. and Alsaber, A. and Al-Bader, B. and Almutairi, F. and Malhas, H. and Pan, J. and Zhanna, K. and Ramadhan, M. and Saleh, M. and Abdullah, M. and Alotaibi, N. and AlNasrallah, N. and Rajan, R. and Hussein, S. and Aboelhassan, W.},
month = {oct},
year = {2022},
abstract = {Objectives: This study aimed to investigate in-hospital mortality rates in patients with coronavirus disease (COVID-19) according to enoxaparin and heparin use. Methods: This retrospective cohort study included 962 patients admitted to two hospitals in Kuwait with a confirmed diagnosis of COVID-19. Cumulative all-cause mortality rate was the primary outcome. Results: A total of 302 patients (males, 196 [64.9%]; mean age, 57.2 ± 14.6 years; mean body mass index, 29.8 ± 6.5 kg/m2) received anticoagulation therapy. Patients receiving anticoagulation treatment tended to have pneumonia (n = 275 [91.1%]) or acute respiratory distress syndrome (n = 106 [35.1%]), and high D-dimer levels (median [interquartile range]: 608 [523;707] ng/mL). The mortality rate in this group was high (n = 63 [20.9%]). Multivariable logistic regression, the Cox proportional hazards, and Kaplan-Meier models revealed that the use of therapeutic anticoagulation agents affected the risk of all-cause cumulative mortality. Conclusion: Age, hypertension, pneumonia, therapeutic anticoagulation, and methylprednisolone use were found to be strong predictors of in-hospital mortality. In elderly hypertensive COVID-19 patients on therapeutic anticoagulation were found to have 2.3 times higher risk of in-hospital mortality. All cause in-hospital mortality rate in the therapeutic anticoagulation group was up to 21%.},
volume = {28},
journal = {Clinical and Applied Thrombosis/Hemostasis},
publisher = {SAGE Publications},
url = {https://doi.org/10.1177/10760296221131802},
}
